Our dedicated team is working each day to pursue biomedical research and technologies directed towards the development of novel therapeutics, including antibody therapeutics and delivery of siRNA-based therapeutics.
Kyowa Kirin Pharmaceutical Research (KKR) contributes to development of first-in-class therapeutics through application of Kyowa Hakko Kirin's (KHK) proprietary antibody technology platforms including KM Mouse, POTELLIGENT®, COMPLEGENT® and AccretaMab®. KKR also seeks to discover novel drugs, drug targets, and create improved platform technologies.
Since its inception, KKR has focused on open innovation through several industry–academia collaborative programs. KKR was established in 1988 and has supported the research of La Jolla Institute for Allergy & Immunology (LJI) for more than 20 years, creating one of the most enduring industry-academic collaborations. Under a research funding agreement, KKR provides a combination of discretionary research funding, and funds dedicated to specific projects, selected by a joint steering committee. KKR receives first negotiation rights to pursue translational research of LJI discoveries. The collaborative efforts between KKR and LJI have led to the development of several promising drug discovery and development programs, including several clinical stage programs. KKR also works with researchers from several other leading academic institutions locally and throughout the U.S. to enhance its network-based drug discovery activities.
As of January 2015, KKR has taken over the in-licensing activities, which we call "External Innovation Engine (EIE)", from its sister subsidiary, BioWa, Inc. The goal of our EIE efforts is to serve as an oversea window for the Research and Development Division of KHK and actively seek external opportunities in products at discovery through pre-clinical stages and in novel innovative technologies to enrich KHK's research product pipeline in the areas of oncology, immunology (inflammation, autoimmune diseases), nephrology, and central nervous system. We also consider strategic collaborations and/or partnerships with pharmaceuticals, biotech, and academia. By transferring the EIE function to KKR, we can work more directly and efficiently with the Open Innovation Department under the Research and Development Division at KHK to accelerate its external innovation activities. Furthermore, we can also utilize KKR's lab activities to focus on exploratory and translational research for some external opportunities.